Founded in 2018, Quoin is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. The company plans to establish a sales infrastructure to commercialize its products in both U.S. and Europe and seeks to enter into strategic licensing partnerships for all other territories. We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved patient populations. To learn more about Quoin Pharmaceuticals please visit our website: www.quoinpharma.com